Rima Al-awar, University of Toronto and Ontario Institute for Cancer Research (OICR), Canada.
“The Optimization and Characterization of WDR5 Binders”
Shaomeng Wang, University of Michigan, USA
“Targeting the MLL complex for new therapeutics”
Jean-François Couture, University of Ottawa, Canada
“Fine-tuning the implementation of histone H3K4me3 by the Ash2L/DPY-30 complex”
Michael Cosgrove, State University of New York Upstate Medical University, USA
"Targeting the Win motif-WDR5 interaction in SET1/MLL family histone methyltransferases"
Kehao Zhao, Novartis, China
“Discovery of PRC2 inhibitors through allosteric Binding to EED”
Mathieu Lupien, Medical Biophysics,University of Toronto, Canada.
”Impact of metabolic adaptation on epigenetic methyltransferases in breast cancer”
Ingo Hartung, Bayer, Germany
“Identification of Chemical Probes for Protein Methyltransferases: SMYD2 and Beyond”
John Wojcik, University of Pennsylvania School of Medicine. USA
“Cross-talk between histone methylation sites in malignant peripheral nerve sheath tumors”
Jocelyn Côté, University of Ottawa, Canada
“CARM1 in Spinal Muscular Atrophy: transcription is only the beginning!”
Paul Delgado-Olguín, The Hospital for Sick Children, Toronto, Canada.
“Repressive Histone Methyltransferases as Regulators of Cardiovascular Development and Disease”
Jean-Claude Guillemot, AFMB, Aix-Marseille University, France
“Viral Methyltransferases”
Dafydd Owen, Pfizer, USA
“From SAM to PFI-5: A different way to tackle SMYD2 inhibition”
